Trial Profile
A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Acronyms SCIG-MG
- 17 Feb 2023 Status changed from recruiting to completed.
- 25 May 2022 Planned End Date changed from 1 Dec 2018 to 1 Apr 2024.
- 25 May 2022 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2024.